NHS Essex Integrated Care Board awarded "DAP C Specialist Fertility Services 27/28" to Guy’s and St Thomas’ NHS Foundation Trust, Bourn Hall Clinic, Cambridge University Hospital Foundation Trust, with a value of £1 (04 November 2026).
NHS Essex Integrated Care Board (herein "the Authority")'s intention to award contracts to deliver Specialist Fertility Services to the patients within NHS Essex's ICB geographical footprint. The contract will be for 12 months months from 01st April 2027 - 31st March 2028. The aggregate contract values are below inclusive VAT noting that these are zero value contracts – paid at local prices- based on planning values for 2026-27 and will be subject to any agreed growth and inflator/deflators applicable to 2027/28. Cambridge University Hospital FT £13,383.00 Bourne Hall Fertility £644,727.00 Care Fertility £0.00 Create Health Limited t/a Create Fertility £27,782.00 Guys & St Thomas Hospital £51,737.00 Herts & Essex Fertility Centre £160,414.00 IVI London Wimpole Ltd £51,560.00 The award details for each provider will reflect a nominal £1.00. The providers are existing providers, who are currently satisfying the requirements of the existing contract. The providers have been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality should be the primary consideration for specialist fertility services due to the highly regulated nature of assisted conception treatment, the clinical risks associated with fertility interventions and the importance of achieving safe, effective patient outcomes. The service specification places significant emphasis on compliance with Human Fertilisation and Embryology Authority (HFEA) standards, CQC requirements, NICE guidance, patient safety, live birth rates, waiting time standards and reducing avoidable harm such as multiple births and treatment complications. Innovation remains important, particularly in supporting improvements in patient experience, clinical outcomes, efficiency and access to treatment. However, any innovation must operate within established regulatory and clinical frameworks and should not compromise the quality, safety or effectiveness of care. Value 30%. It is a statut
A weekly round-up of new UK public sector contracts. No spam, unsubscribe any time.